Budesonide dry-powder inhalation - Sofotec

Drug Profile

Budesonide dry-powder inhalation - Sofotec

Alternative Names: Budecort 200 Novolizer; Budesonide Novolizer; Novolizer Budesonide; Novopulmon 200 Novolizer; S 1320 dry-powder inhalation - Sofotec; Tafen Novolizer

Latest Information Update: 19 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Degussa; Sofotec; University of Groningen
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 05 Aug 2016 Meda has been acquired by Mylan
  • 15 Mar 2016 Biomarkers information updated
  • 07 Nov 2003 Budesonide 200µg Novolizer® is available for licensing outside Germany and major West European countries (http://www.viatris.com/)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top